Why Are LogicBio Therapeutics Shares Skyrocketing Today?
Benzinga
Published Oct 03, 2022 12:21
Updated Oct 03, 2022 13:10
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
- AstraZeneca Plc's (NASDAQ: NASDAQ:AZN) subsidiary, Alexion (NASDAQ:ALXN), has agreed to acquire LogicBio Therapeutics Inc (NASDAQ: LOGC) for $2.07 per share. Both boards have unanimously approved the transaction.
- Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock.
- It plans to retain LogicBio employees at their current location.
- Also Read: LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial.
- The proposed acquisition brings LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion's growth in genomic medicines.
- Fred Chereau, President and Chief Executive Officer, LogicBio, said, "Through this acquisition, we strive to accelerate our research in gene editing and AAV capsid development and together move the field of genomic medicine forward."
- LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases and a platform designed to improve viral vector manufacturing processes.
- Price Action: LOGC shares are up 633.9% at $2.00 during the premarket session on the last check Monday.
Read the original article on Benzinga
Get The App
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.